#United States #PTC Therapeutics #Warren #Huntington's Disease #Votoplam

Positive Results from PIVOT-HD Study

In a recent announcement, PTC Therapeutics, Inc. (NASDAQ: PTCT) has reported encouraging outcomes from the 24-month interim analysis of its PIVOT-HD study, which investigates the long-term effects of Votoplam on patients with Huntington's disease (HD). The results indicate significant potential for Votoplam to not only delay the progression of the disease but also to maintain a favorable safety profile.

Key Findings

Dose-Dependent Benefits

The analysis highlighted a notable dose-dependent impact on the Composite Unified Huntington's Disease Rating Scale (cUHDRS); participants receiving a 10 mg dose of Votoplam demonstrated a 52% reduction in disease progression, while those on the 5 mg dose exhibited a 28% slowdown. This is particularly encouraging for early-stage patients suffering from HD, a genetic neurodegenerative disorder characterized by severe motor and cognitive decline.

Safety Profile

Importantly, the interim analysis from PIVOT-HD revealed no treatment-related increases in neurofilament light chain protein (NfL) levels, a crucial biomarker for neuronal damage. In fact, average NfL levels remained below baseline after 24 months of treatment for both dosing groups. This contrasts sharply with historical data indicating that NfL levels typically rise in untreated HD patients.

Study Background

The PIVOT-HD study originally began as a 12-month placebo-controlled trial, primarily focused on determining the pharmacodynamic effects and safety of two dosing levels of Votoplam, 5 mg and 10 mg. Participants included individuals with Stage 2 and Stage 3 HD, and the study met its primary endpoint of significant blood levels of Huntingtin (HTT) protein reduction at the end of 12 weeks, with continued lowering over the subsequent months.

Following this initial phase, participants were invited to enroll in the PIVOT-HD extension study, where all subjects were treated with Votoplam. This extension aims to evaluate the long-term safety and efficacy of the therapy, establishing a clearer understanding of Votoplam's potential.

Next Steps

On a broader scale, during a conference call held on April 28, 2026, PTC CEO Dr. Matthew B. Klein expressed optimism regarding the promising results. These findings provide a solid foundation for the upcoming Phase 3 INVEST-HD study, initiated by Novartis, which will focus on an extensive placebo-controlled trial enrolling roughly 770 early-stage HD patients. This trial aims to solidify the primary endpoint of cUHDRS change from baseline over 36 months, which will be a crucial measure for regulatory assessments moving forward.

The partnership between PTC and Novartis continues to evolve with the shared goal of advancing Votoplam from the laboratory to the clinic. PTC's diligent efforts to explore the full therapeutic potential of Votoplam may lead to a transformative option for individuals grappling with this devastating condition.

About Huntington's Disease

Huntington's disease remains a critical public health challenge due to its hereditary nature and impactful symptoms ranging from motor dysfunctions to cognitive decline. Currently, no treatments exist that alter the course of the disease, making breakthroughs like Votoplam particularly significant.

Conclusion

As PTC Therapeutics continues to make strides in Huntington's disease research, the positive data from the PIVOT-HD study shines a hopeful light for patients and families affected by this disorder. The potential for Votoplam to offer meaningful improvement in quality of life and disease management represents a compelling advance in the ongoing battle against Huntington's disease.